UBS AM’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $3M | Sell |
|
|||||
|
2025
Q2 | $6.2M | Buy |
|
|||||
|
2025
Q1 | $3.36M | Buy |
|
|||||
|
2024
Q4 | $3.02M | Buy |
|
|||||
|
2024
Q3 | $2.96M | Sell |
|
|||||
|
2024
Q2 | $2.68M | Buy |
|
|||||
|
2024
Q1 | $1.25M | Hold |
|
|||||
|
2023
Q4 | $1.48M | Buy |
|
|||||
|
2023
Q3 | $1.67M | Hold |
|
|||||
|
2023
Q2 | $1.97M | Hold |
|
|||||
|
2023
Q1 | $1.97M | Buy |
|
|||||
|
2022
Q4 | $2.34M | Sell |
|
|||||
|
2022
Q3 | $2.57M | Buy |
|
|||||
|
2022
Q2 | $2.12M | Sell |
|
|||||
|
2022
Q1 | $3.76M | Buy |
|
|||||
|
2021
Q4 | $2.83M | Buy |
|
|||||
|
2021
Q3 | $2.51M | Sell |
|
|||||
|
2021
Q2 | $3.7M | Buy |
|
|||||
|
2021
Q1 | $2.37M | Sell |
|
|||||
|
2020
Q4 | $1.88M | Sell |
|
|||||
|
2020
Q3 | $3.99M | Hold |
|
|||||
|
2020
Q2 | $5.53M | Buy |
|
|||||
|
2020
Q1 | $233K | Sell |
|
|||||
|
2019
Q4 | $440K | Buy |
|
|||||
|
2019
Q3 | $211K | Buy |
|
|||||
|
2019
Q2 | $250K | Buy |
|
|||||
|
2019
Q1 | $498K | Buy |
|
|||||
|
2018
Q4 | $388K | Hold |
|
|||||
|
2018
Q3 | $366K | Hold |
|
|||||
|
2018
Q2 | $275K | Sell |
|
|||||
|
2018
Q1 | $287K | Buy |
|
|||||
|
2017
Q4 | $207K | Hold |
|
|||||
|
2017
Q3 | $221K | Buy |
|
|||||
|
2017
Q2 | $221K | Sell |
|
|||||
|
2017
Q1 | $392K | Buy |
|
|||||
|
2016
Q4 | – | Sell |
|
|||||
|
2016
Q3 | $120K | Hold |
|
|||||
|
2016
Q2 | $77K | Hold |
|
|||||
|
2016
Q1 | $77K | Sell |
|
|||||
|
2015
Q4 | $282K | Sell |
|
|||||
|
2015
Q3 | $339K | Buy |
|
|||||
|
2015
Q2 | $426K | Buy |
|
|||||
|
2015
Q1 | $236K | Buy |
|
|||||
|
2014
Q4 | $300K | Buy |
|
|||||
|
2014
Q3 | $211K | Buy |
|
|||||
|
2014
Q2 | $261K | Hold |
|
|||||
|
2014
Q1 | $217K | Hold |
|
|||||
|
2013
Q4 | $156K | Buy |
|